A Phase 4 interventional study of hemodynamics-based individualized antihypertensive therapy and guideline-based conventional treatment in Hypertension, sponsored by The Third Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-21.
Sponsored by The Third Xiangya Hospital of Central South University · Phase 4, Interventional, and Treatment
The goal of this clinical trial is to explore the clinical efficacy and safety of individualized antihypertensive medication guided by hemodynamic phenotyping. The main questions it aims to answer are:
Participants will:
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's planned enrollment of 240 is above the median of 90 across 4,995 interventional studies indexed under Hypertension.
Browse Hypertension studies →The Third Xiangya Hospital of Central South University is the lead sponsor of 95 studies on the registry; 49 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The antihypertensive strategy is individualized according to the patient's hemodynamic indices: High-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally. High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally. Hypervolemic type: Indapamide Tablets 2.5mg, once daily, orally.
Drug: hemodynamics-based individualized antihypertensive therapy
Developing a monotherapy antihypertensive treatment plan for participants based on the 2024 Chinese hypertension guidelines
Drug: guideline-based conventional treatment
The antihypertensive strategy is individualized according to the patient's hemodynamic indices: High-resistance type: Amlodipine Besylate Tablets 5mg, once daily, orally. High cardiac output type: Metoprolol Sustained-Release Tablets 47.5mg, once daily, orally. Hypervolemic type: Indapamide Tablets 2.5mg, once daily, orally. Participants will take the therapy for 8 weeks.
Also known as: individualized therapy
Developing a monotherapy antihypertensive treatment plan for participants based on the 2024 Chinese hypertension guidelines. Participants will take this treatment for 8 weeks.
Also known as: conventional treatment
Difference in office systolic blood pressure reduction
Difference in office systolic blood pressure reduction between two groups.
Time frame: 8 weeks after treatment
Reduction difference in office systolic blood pressure
Reduction difference in office systolic blood pressure between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Reduction difference in office diastolic blood pressure
Reduction difference in office diastolic blood pressure between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Reduction difference in office mean blood pressure
Reduction difference in office mean blood pressure between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Difference in pulse rate changes
Difference in pulse rate changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Difference in blood pressure target rate
Difference in blood pressure target rate (both systolic and diastolic blood pressure will be measured) between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Difference of systemic vascular resistance index (SVRI) changes
Difference of systemic vascular resistance index (SVRI) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Difference of cardiac index (CI) changes
Difference of cardiac index (CI) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Difference of thoracic fluid content (TFC) changes
Difference of thoracic fluid content (TFC) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 4 weeks after treatment
Reduction difference in office diastolic blood pressure
Reduction difference in office diastolic blood pressure between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 8 weeks after treatment
Reduction difference in office mean blood pressure
Reduction difference in office mean blood pressure between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 8 weeks after treatment
Difference in pulse rate changes
Difference in pulse rate changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy
Time frame: 8 weeks after treatment
Difference in blood pressure target rate
Difference in blood pressure target rate (both systolic and diastolic blood pressure will be measured) between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy
Time frame: 8 weeks after treatment
Difference of systemic vascular resistance index (SVRI) changes
Difference of systemic vascular resistance index (SVRI) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 8 weeks after treatment
Difference of cardiac index (CI) changes
Difference of cardiac index (CI) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 8 weeks after treatment
Difference of thoracic fluid content (TFC) changes
Difference of thoracic fluid content (TFC) changes between two groups and among subgroups of hemodynamic phenotyping in individualized antihypertensive therapy.
Time frame: 8 weeks after treatment
Adverse events
Adverse events between two groups
Time frame: Eight weeks
Serious adverse events
Serious adverse events between two groups
Time frame: Eight weeks
Adverse drug reaction
Adverse drug reaction between two groups
Time frame: Eight weeks
No study locations are listed for this record.
Plan to share: Yes — Coded data (without personal identification information) used and analysed during the study will be available to researchers one year after the publication date of the manuscript from the corresponding author on reasonable request, with the approval of the steering committee and Research Center for Clinical Trials of the Third Xiangya Hospital of Central South University, on signing of a data access agreement.
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Xiangya Hospital of Central South University